Long-Term Improvements Observed in Tralokinumab-Treated Patients with Moderate-to-Severe Atopic Dermatitis: an ECZTEND Interim Analysis

Main Article Content

Andrew Blauvelt
Oregon Medical Research Center, Portland, OR, USA

Jean-Philippe Lacour
Department of Dermatology, University Hospital of Nice Côte d’Azur, Nice, France

Darryl Toth
Probity Medical Research, Waterloo, ON, Canada

Vivian Laquer
First OC Dermatology, Fountain Valley, CA, USA

Stefan Beissert
Department of Dermatology, University of Dresden, Dresden, Germany

Andreas Wollenberg
Department of Dermatology and Allergology, Ludwig-Maximilian University of Munich, Munich, Germany

Pedro Herranz
Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain

Andrew Pink
St. John's Institute of Dermatology, Guy’s and St. Thomas’ Hospitals, London, UK

Ketty Peris
Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy

Stine Fangel
LEO Pharma A/S, Ballerup, Denmark

Hidehisa Saeki
Department of Dermatology, Nippon Medical School, Tokyo, Japan

Keywords

tralokinumab, atopic dermatitis, ECZTEND

Abstract

N/A

References

1. Weidinger S, Novak N. Lancet. 2016;387:1109-22.

2. Eckert L, et al. J Am Acad Dermatol. 2017;77:274-9.e273.

3. Silverberg JI, et al. Ann Allergy Asthma Immunol. 2018;121:340-7.

4. Dalgard FJ, et al. J Invest Dermatol. 2015;135:984-91.

5. Bieber T. Allergy. 2020;75:54-62.

6. Tsoi LC, et al. J Invest Dermatol. 2019;139:1480-9.

7. Popovic B, et al. J Mol Biol. 2017;429:208-19.

8. Wollenberg A, et al. Br J Dermatol. 2021;184:437-49.

9. Silverberg JI, et al. Br J Dermatol. 2021;184:450-63.

10. Leshem YA, et al. Br J Dermatol. 2015;172:1353-7.

11. Hongbo Y, et al. J Invest Dermatol. 2005;125:659-64.

Article Sidebar

Poster PDF
Published
Nov 5, 2021
DOI https://doi.org/10.25251/skin.5.supp.59

Article Details

How to Cite
[1]
Blauvelt, A. , Lacour, J.-P., Toth, D., Laquer, V., Beissert, S., Wollenberg, A., Herranz, P., Pink, A., Peris, K. , Fangel, S. and Saeki, H. 2021. Long-Term Improvements Observed in Tralokinumab-Treated Patients with Moderate-to-Severe Atopic Dermatitis: an ECZTEND Interim Analysis. SKIN The Journal of Cutaneous Medicine. 5, 6 (Nov. 2021), s59. DOI:https://doi.org/10.25251/skin.5.supp.59.
Issue
Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 8 9 10 > >>